Allogene: Developed universal CAR-T with the help of oncologists across the United States

October 13, 2022 /eMedClub News/-CAR-T therapy is a breakthrough treatment that has been a boon to many oncology patients, but its pricing and preparation process have significantly limited
accessibility.
A new real-world survey in the United States found that 82% of respondents were willing to receive treatment with CAR-T therapy, but long waiting times and manufacturing restrictions prevented many eligible patients from receiving treatment
.
In response to this, Allogene, a leader in allogeneic CAR-T therapy, recently launched a joint development program for generic CAR-T therapies - CART Together™, which aims to convene oncologists from well-known research institutions in the United States to jointly develop universal CAR-T therapies
.

According to an Allogene press release, CAR-T therapies that are already available in the U.
S.
often take longer to prepare, leading many clinicians to make difficult decisions about who will get the scarce CAR-T product
.
A recent real-world survey of 50 U.
S
.
hemato-oncologists, physician assistants, nurse practitioners, and registered nurses at academic centers with CAR-T treatment capabilities systematically presented the current state of CAR-T therapy in the United States and shed light on some new perspectives on the future development of CAR-T products.

The results of the survey show that:

1.
Only half of advanced cancer patients who meet the conditions for treatment with autologous CAR-T therapy approved for marketing have received treatment
.

2.
While 82% of respondents agreed to receive CAR-T therapy, long wait times and manufacturing restrictions prevented many eligible patients from receiving treatment
.

3.
Of the patients eligible for treatment, only 12% were able to receive treatment within 1 month, and about 40% had to wait up to 6 months or more to receive treatment
.

4.
For eligible patients, disease progression, manufacturing capacity, and complications are the biggest obstacles
.

5.
Respondents identified increasing patient demand, manufacturing capacity and treatment time as the top three challenges
for CAR-T therapies in the future.

In order to break through the current bottleneck of CAR-T therapy, CART Together brings together oncologists from nationally renowned research institutions to unite oncologists across the United States to break through the existing bottleneck and develop universal CAR-T cell therapy
.
According to an Allogene press release, a single-production generic CAR-T product has the potential to treat about 100 patients, and a mass-produced CAR-T product is expected to treat 20,000 patients
per year.

The inaugural CAR T Together has brought together many well-known American oncologists, including Maung MyoHtut, MD, associate professor of multiple myeloma in the Department of Hematology and Hematopoietic Cell Transplantation in the City of Hope, Fred Locke, MD, chair of the Department of Blood and Bone Marrow Transplantation and Cellular Immunotherapy at Moffitt Cancer Center, Dr.
Javier Munoz, director of the Mayo Clinic lymphoma program, and Sumanta, co-director of the City of Hope Kidney Cancer Program KumarPal M.
D.
, among others
.

It is worth mentioning that the pivotal phase II trial of Allogene's first allogeneic CAR-T product, ALLO-501A, has also been officially launched
.
However, in recent years, the progress of general CAR-T therapy has not been smooth, many projects have been suspended, and Servier has recently directly withdrawn from the general CAR-T project
that was snapped up with Pfizer.
Of course, a track cannot be defined because of a momentary failure, and a variety of breakthrough treatments are not smooth at first, and universal cell therapy is the trend of the times, and no matter how difficult it is, it must be vigorously advanced
.
This time, Allogene can be described as bringing together many top scholars in the United States, and believes that it can bring breakthroughs faster in the development of general CAR-T therapy
.

Resources:

1.
style="white-space: normal;outline: 0px;max-width: 100%;color: rgb(34, 34, 34);font-family: system-ui, -apple-system, BlinkMacSystemFont, "Helvetica Neue", "PingFang SC", "Hiragino Sans GB", "Microsoft YaHei UI", "Microsoft YaHei", Arial, sans-serif;letter-spacing: 0.
544px;background-color: rgb(255, 255, 255);text-align: center;box-sizing: border-box !important;overflow-wrap: break-word !important;margin-bottom: 0px;">

——List of recent popular events——

▼October 13, Sino-US Double Report Cell Bank Verification Strategy Seminar